GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » YoY EBITDA Growth

HOWL (Werewolf Therapeutics) YoY EBITDA Growth : -78.65% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Werewolf Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Werewolf Therapeutics's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was -78.65%.

Werewolf Therapeutics's EBITDA per Share for the three months ended in Sep. 2024 was $-0.34.

Werewolf Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Werewolf Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Werewolf Therapeutics YoY EBITDA Growth Chart

Werewolf Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
- -124.52 -8.91 32.42 50.11

Werewolf Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.94 15.79 -8.26 -241.35 -78.65

Werewolf Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Werewolf Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.911--1.826)/ | -1.826 |
=50.11 %

Werewolf Therapeutics's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EBITDA Growth (Q: Sep. 2024 )
=(EBITDA per Share (Q: Sep. 2024 )-EBITDA per Share (Q: Sep. 2023 )) / | EBITDA per Share (Q: Sep. 2023 )) |
=(-0.343--0.192)/ | -0.192 |
=-78.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Werewolf Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Werewolf Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Werewolf Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » YoY EBITDA Growth
Comparable Companies
SGMT TSBX HRGN GLYC KOD ARMP VERU CVM SLNCF ATOS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472
Website
https://www.werewolftx.com
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Executives
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Luke Evnin director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Meeta Chatterjee director C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Chulani Karunatilake officer: Chief Technology Officer 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Reid Leonard officer: Chief Operating Officer 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mpm Oncology Innovations Fund Lp 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Longwood Fund Iii Gp, Llc 10 percent owner 800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199
Derek Dirocco director 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Moshe Arkin 10 percent owner 6 HACHOSHLIM ST., HERZELIA L3 4672406
Alon Lazarus director, 10 percent owner C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Daniel J Hicklin director, 10 percent owner, officer: See Remarks
Sphera Funds Management Ltd. 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Management Lp 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Gp Ltd. 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520